-46.5%
APLD vs MRNA
+945.0%
-991.5%
-67.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.7% | +13.1% | -19.8% | -7.2% |
| 7D | -18.5% | +20.6% | -39.2% | -19.2% |
| 30D | -32.8% | +27.1% | -59.9% | -33.4% |
| 3M | -46.9% | +353.4% | -400.3% | -52.2% |
| 6M | -53.4% | +446.3% | -499.6% | -61.4% |
| YTD | -32.3% | +776.2% | -808.4% | -52.8% |
| 1Y | -46.5% | +987.9% | -1,034.4% | -64.1% |
| All | -46.5% | +945.0% | -991.5% | -64.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling